© 2006 American Thoracic Society
Negative Studies Deserve More AttentionFrom the Authors:
We thank Dr. Gama de Abreu for his letter regarding our recent article (1). He raises important questions regarding the methodology used to ventilate patients during our trial and the potential utility of perfluorocarbon therapy in general for the management of adult acute respiratory distress syndrome (ARDS). When a clinical trial is designed, investigators struggle to ensure that the control group receives an approach to therapy that is considered at the time of study design to be standard or the best possible based on the best available data. At the time our study began (1998), we based our ventilatory strategies on the best available data that addressed lung protection (1). The mortality in all groups was 15% (control arm) to 26%, equivalent to or better than any other study evaluating ventilatory strategy in ARDS. Although we only enrolled patients 65 yr of age or younger, we obtained these low mortality rates even though our oxygenation entry criteria were more rigorous than those in published ARDS trials, except that of Villar and coworkers (2). Specifically, patients had to first demonstrate a PaO2/FIO2 less than 200 mm Hg on an FIO2 of In response to Dr. Gama de Abreu's second question, at the time we began our trial there were laboratory data available on partial liquid ventilation (PLV) with high-frequency ventilation (46). These studies compared high-frequency ventilation and conventional ventilation with and without PLV. In two of the studies, PLV was better able to improve gas exchange (both high-frequency and conventional) (5, 6), and in the third, no differences were observed (4). Thus, to our knowledge there were no important negative experimental data on PLV that used alternate ventilatory modes in the control group. As Dr. Gama de Abreu indicates, we felt strongly that the negative results from our trial needed to be published so that others would not utilize the approach to perfluorocarbon therapy in ARDS that we used. We agree that it is critical for negative trials to be published, since we can learn just as much from a negative trial as we do from a positive trial, even though the results may not be as exciting.
Massachusetts General Hospital, Boston, Massachusetts
University of Toronto, Toronto, Ontario, Canada FOOTNOTES Conflict of Interest Statement: R.M.K. received a $65,000 grant from Alliance Pharmaceuticals in 1999 to support studies of partial liquid ventilation in animal models. A.S.S. has been a paid consultant to Maquet in the field of mechanical ventilation ($10,000/yr). He chaired a DSMB for Leo Pharma in relation to a surfactant trial ($10,000/yr), and was on the Alliance advisory board for the trial presented in this publication, but received no financial compensation for this. REFERENCES
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||